We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First in Diagnostics – Solid-State Technology Device Accredited in EU

By LabMedica International staff writers
Posted on 06 Oct 2014
The CE marking has been given for healthcare professional use of a new PT/INR blood-testing disposable diagnostic strip as part of the world’s first accredited diagnostic device based on a micro-electromechanical system (MEMS).

The CE marking accreditation, achieved by Microvisk Ltd (St. More...
Asaph, UK) for its CoagMax PT/INR system, is a major step forward in blood testing technology. Microvisk’s patented microcantilever sensor technology determines blood clotting speed from a finger-prick sample, with results displayed on its compact CoagMax handheld reader. The PT/INR strip, which uses the standard international PT (Prothrombin Time) or INR (International Normalized Ratio) test on a drop of patient’s whole blood from a finger prick, measures fluid viscosity, combining accurate, dependable, lab-quality results with exceptional ease of use. The strip sensors detect blood changes to a gel-like substance and assess whether viscosity is within acceptable range for the patient’s medication.

Patient clotting speed is measured by multilayered MEMS sensors, incorporating a cantilever on the strip surface to measure the fluid viscosity. An embedded microchip stores calibration data and the CoagMax reader automatically rejects any strip compromised by prior use.

“CE marking for CoagMax takes us close to the runway for product launch to the European healthcare professional market and beyond,” said Microvisk CEO Jim Thurlow. He added, “The achievement of CE marking of a medical diagnostic device based on a tiny MEMS sensor is a major milestone for Microvisk – and opens up further possibilities for this pioneering technology.”

Initial application of the technology is for monitoring patients taking anticoagulants such as Warfarin, to minimize risk from life-threatening blood clots and help manage correct dosage. Microvisk’s platform technology is unique in medical diagnostics as a robust, solid-state system with the simplicity to revolutionize point-of-care and home testing. With patients on anticoagulants needing regular tests to confirm correct dosage levels, there’s an increasing trend for self-testing at home. The Microvisk CoagMax reader and PT/INR strip enable patients to quickly and conveniently test blood clotting, as diabetics test for glucose.

The CoagMax PT/INR system is distinct from other existing technology, which relies on more complex and less user-friendly optical analysis or chemical reaction-based measurement. The CoagMax meter reduces healthcare cost as well as patient time and inconvenience for clinic attendance and laboratory services. Requiring only 8 µL of blood, less than competing systems, also means less pain for users.

Related Links:

Microvisk 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.